Regulatory Context for Pulmonary

Pulmonary medicine operates within one of the most densely regulated areas of U.S. healthcare, shaped by federal statute, agency rulemaking, accreditation standards, and state licensing law. The framework governs everything from how pulmonologists achieve board certification to how hospitals must document and reimburse the diagnosis of conditions such as COPD, pulmonary fibrosis, and pulmonary hypertension. Understanding this structure clarifies the procedural constraints and quality benchmarks that define care delivery across the specialty.

How the regulatory landscape has shifted

The passage of the Affordable Care Act (ACA) in 2010 fundamentally restructured quality reporting obligations for pulmonary providers. Before that legislation, physician quality reporting was largely voluntary. Post-ACA, the Centers for Medicare & Medicaid Services (CMS) introduced mandatory participation in the Physician Quality Reporting System (PQRS), later absorbed into the Merit-based Incentive Payment System (MIPS) under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Under MIPS, a pulmonologist's Medicare reimbursement can be adjusted upward or downward by a percentage tied to performance scores across 4 categories: quality, cost, improvement activities, and promoting interoperability (CMS MIPS overview, ecfr.gov 42 CFR §414.1305).

Separately, the No Surprises Act, effective January 2022, created new disclosure obligations for out-of-network billing that apply directly to specialists including pulmonologists who practice in hospital outpatient settings. The Act is implemented through joint rules issued by CMS, the Department of Labor, and the Department of Health and Human Services (HHS).

Occupational lung disease surveillance also underwent significant regulatory expansion following updates to the Mine Safety and Health Administration (MSHA) silica dust exposure rule, finalized in 2024, which lowered the permissible exposure limit (PEL) for respirable crystalline silica to 50 micrograms per cubic meter of air as an 8-hour time-weighted average — a threshold that directly affects clinical reporting for conditions covered under occupational lung disease protocols.

Governing sources of authority

Pulmonary medicine draws regulatory authority from at least 5 distinct source types:

Federal statutes — The Social Security Act (Title XVIII for Medicare, Title XIX for Medicaid) governs coverage determinations for pulmonary procedures including pulmonary function tests, bronchoscopy, and CT chest scans.
Federal agency rules — CMS issues National Coverage Determinations (NCDs) and Local Coverage Determinations (LCDs) that set the evidentiary threshold for reimbursing specific diagnostic and therapeutic procedures.
OSHA standards — The Occupational Safety and Health Administration (OSHA) sets permissible exposure limits for respiratory hazards under 29 CFR Part 1910 and Part 1926. These limits interact directly with clinical thresholds used in diagnosing occupationally induced pulmonary disease.
Accreditation standards — The Joint Commission accredits hospitals and requires compliance with respiratory care service standards, including staff credentialing and equipment maintenance for oxygen delivery systems relevant to oxygen therapy.
State medical practice acts — Each state's medical board defines the scope of practice, prescriptive authority, and licensure requirements for pulmonologists operating within that jurisdiction.

Federal vs state authority structure

Federal authority is dominant in insurance coverage, drug approval, device clearance, and occupational exposure standards. The Food and Drug Administration (FDA) governs approval of inhaled therapeutics and medical devices used in inhaler therapy and CPAP/BiPAP therapy under the Federal Food, Drug, and Cosmetic Act (21 U.S.C. §301 et seq.).

State authority governs licensure of practitioners, hospital facility licensing, scope of practice for respiratory therapists, and Medicaid coverage expansions beyond federal minimums. A respiratory therapist licensed in California operates under the California Respiratory Care Practice Act (Business and Professions Code §3700–3780), a framework that is structurally distinct from Texas or New York licensing codes — creating a fragmented national landscape for allied pulmonary professionals.

The federal-state tension is most visible in Medicaid. States set their own pulmonary rehabilitation coverage policies within federal minimum requirements, producing significant cross-state variation in patient access. The broad overview of how these intersecting rules shape the specialty is accessible through the main topic index.

Named bodies and roles

The following institutions hold defined regulatory and standard-setting roles within pulmonary medicine:

Centers for Medicare & Medicaid Services (CMS) — Primary federal payer and coverage rule issuer; administers MIPS quality reporting affecting pulmonologist reimbursement.
Food and Drug Administration (FDA) — Approves all inhaled medications, nebulizers, ventilators, and bronchoscopic devices used in pulmonary practice.
Occupational Safety and Health Administration (OSHA) — Sets and enforces workplace respiratory hazard limits under 29 CFR Part 1910.1000.
Mine Safety and Health Administration (MSHA) — Enforces exposure controls for mining environments tied to coal workers' pneumoconiosis and silicosis surveillance.
The Joint Commission (TJC) — Accredits facilities providing pulmonary care and sets respiratory service standards.
American Board of Internal Medicine (ABIM) — Certifies pulmonologists through its Pulmonary Disease and combined Pulmonary Disease and Critical Care Medicine examination pathways.
American Thoracic Society (ATS) and American College of Chest Physicians (CHEST) — Publish clinical practice guidelines that, while not legally binding, are cited in payer LCD policies and malpractice standards of care.
National Institute for Occupational Safety and Health (NIOSH) — Conducts the Coal Workers' Health Surveillance Program and issues health hazard evaluations relevant to occupational pulmonary disease.

The distinction between regulatory bodies (CMS, FDA, OSHA) and standard-setting bodies (ATS, CHEST, ABIM) is critical: regulatory bodies carry enforcement authority and can impose penalties, while standard-setting bodies produce guidelines that inform but do not independently compel compliance.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)